Summary of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings as of Jun 27, 2018

June 27, 2018 - By Ricky Cave

Big Money Sentiment decreased to 1.19 in Q1 2018. It has change of 0.01, from 2017Q4’s 1.2. The ratio dropped due to Aerie Pharmaceuticals, Inc. positioning: 18 sold and 46 reduced. 17 funds took holdings and 59 increased holdings. Investors holded 34.86 million in 2017Q4 but now own 39.43 million shares or 13.11% more.
State Board Of Administration Of Florida Retirement Systems invested in 0% or 17,741 shs. Swiss Bancorp has invested 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). 31,792 are held by Rhumbline Advisers. Voya Inv Mgmt Ltd Com reported 455,450 shs. Northern reported 433,548 shs or 0.01% of all its holdings. Alyeska Investment Gp Ltd Partnership holds 301,103 shs. Harvey Management invested in 0.48% or 23,519 shs. Perigon Wealth Mgmt Ltd owns 1,098 shs. Atwood Palmer Incorporated invested in 200 shs. The Massachusetts-based State Street Corp has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Manufacturers Life Insurance The reported 25,409 shs stake. Jpmorgan Chase accumulated 7,619 shs. Teacher Retirement System Of Texas invested in 0% or 6,903 shs. 5,766 are held by United Services Automobile Association. C Wide Gp A S holds 0.06% or 72,739 shs in its capital.

Aerie Pharmaceuticals, Inc. had 4 sales and 2 insider buys since May 21, 2018. This’s net activity of $13.13 million. The insider Cagle Gerald D. bought $50,245. On Wednesday, June 6 Shares for $9.34M were sold by ANIDO VICENTE JR.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Total analysts of 6 have positions in Aerie Pharma (NASDAQ:AERI) as follows: 6 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 2, 2018 according to StockzIntelligence Inc Aerie Pharma has 10 analyst reports. On Wednesday, May 9 the firm earned “Buy” rating by H.C. Wainwright. On Tuesday, May 8 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Cantor Fitzgerald. On Wednesday, February 28 the company was maintained by Cantor Fitzgerald. On Tuesday, January 2 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Stifel Nicolaus. The stock rating was maintained by Mizuho with “Buy” on Wednesday, May 9. On Thursday, March 1 the firm earned “Buy” rating by H.C. Wainwright. In Wednesday, January 24 report Canaccord Genuity maintained it with “Buy” rating and $86.0 target. On Thursday, March 29 the firm has “Buy” rating given by Mizuho. On Friday, February 16 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given by H.C. Wainwright. Listed here are Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) PTs and latest ratings.

09/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0000 Maintain
09/05/2018 Broker: Mizuho Rating: Buy New Target: $77.0000 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0000 Maintain
29/03/2018 Broker: Mizuho Rating: Buy New Target: $87.0000 Maintain
01/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0 Maintain
16/02/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $78 Reinitiate
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $78 Initiates Coverage On
24/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $86.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $80.0 Maintain

Ticker’s shares touched $68.5 during the last trading session after 0.66% change.Aerie Pharmaceuticals, Inc. has volume of 105,247 shares. Since June 27, 2017 AERI has declined 8.48% and is downtrending. The stock underperformed the S&P 500 by 21.05%.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The company has $2.71 billion market cap. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Last it reported negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

A couple more Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were published by: Businesswire.com which released on June 02, 2018 “Aerie Pharmaceuticals to Present at the NASDAQ 38”, also Gurufocus.com on June 09, 2018 published “Aerie Pharmaceuticals Inc (AERI) CEO Vicente Jr Anido Sold $9.3 million of Shares”, the next Businesswire.com is “Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel” on June 18, 2018. Benzinga.com has article titled “Benzinga’s Daily Biotech Pulse: FDA Greenlights Tandem Diabetes’ Insulin Pump, More IPOs On Tap”.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.